The heat on the phosphatidylinositol 3-kinase (PI3K) inhibitor class is ratcheting up, with TG Therapeutics, Inc.’s Ukoniq joining the ranks of withdrawn products and an FDA advisory committee addressing the class-wide safety concerns.
The withdrawal of Ukoniq from the market as well as the pulling of applications for Ukoniq and an anti-CD20 antibody,...





